Alexios S. Antonopoulos

#EHJIMP submissions for #AI in #CVImaging are open. For more information 👇 @EHJIMPEiC @ESC_Journals @vass_vassiliou @Doc_Tiger @aniela_petrescu @AnnaKateBarton @BernardAnne7 @chiarabd @rafavidalperez @RJurcut @s_e_petersen @ThomasTreibel @AlAntonopoulos @charles_driving @denisamuraru @Sarah_Moharem @VDelgadoGarcia

Can multimodality imaging help diagnose rare #cardiactumors? Check the #ImageOfTheMonth featuring a case of giant cavernous #hemangioma in the RV, diagnosed using ECHO, CCT, and CMR bit.ly/HJC_tumor @hjc_ed @zhengliumdpumc #echoFirst #yesCCT #whyCMR #Cardiacimaging.

#ECG of the first diagnosed case with #ARVC Naxos disease presented by @ATsatsopoulou at #MPD2024 Congress in Athens #cardiomyopathies, #cardiotwiter

Join the heartbeat revolution! Submit your manuscript to this super-hot Special Issue we're launching at Frontiers, about AI-powered arrhythmia detection and prediction. 🧠💓 @OikonomouVangel, @AlAntonopoulos, Polydoros Kampaktsis

Just published @TheLancet CCTA with FAI score can be used to assess coronary inflam risk regardless of obstruction/plaque/calcification - unlocking unrivalled risk assessment and targeted treatment. Congrats to Ken & Elizabeth for leading this analysis. doi.org/10.1016/S0140-…

Imagenetics for precision medicine in Dilated Cardiomyopathy 🔥 @AlAntonopoulos ahajournals.org/doi/10.1161/CI…

Welcome to #Athens! We are ready for the #ESCPrev2024! An exciting meeting is coming! Join us tomorrow morning! @escardio @ESCardioNews @MichaelPapadak2 @EAPCPresident @hcs_young @hcs @AlAntonopoulos @shantsila @LiverpoolCCS @Rhythmisit @acardioEKPA

Great to have this preprint out - In 50k CMRs of the UK Biobank, we identified common and rare genetic factors influencing trabeculation, identified modifiers, and assessed the relationship with cardiomyopathies and imaging-derived traits. @DrDeclanORegan medrxiv.org/cgi/content/sh…

"ECG Biometrics"☝️👁️👥 Those who follow our work know that we are committed to enhancing the ability to diagnose cardiovascular conditions directly from images of ECGs. This includes rhythm/conduction problems but also structural heart diseases. (links to papers in @NatureComms and @CircAHA in 🧵) Often, developing these models is limited by a number of examples for a condition. In this technical contribution led by @Veer_Sangha_, @cards_lab member, and current @rhodes_trust scholar @UniofOxford, we report that different ECGs from the same person separated in time have shared features. These "ECG Biometrics" can be used to enable efficient model development by training a model to learn features that define similarity and dissimilarity across individuals. And then start training models for conditions after that point. We see large gains in performance. Now out in @JAMIA_Journal! Thanks to our team: @aakhunte @ekoikonomou @giholste @jbmortazavi, and Atlas @VITAGroupUT academic.oup.com/jamia/advance-…

Dear Faculty, Fellows, Residents and Friends Welcome to another @MonteHeart Imaging and Clinical Lectures Friday, February 9th, 2024 From 12:00 pm EST – 1:00 pm EST Click On Our einsteinmed.zoom.us/j/94170046499 International numbers available: einsteinmed.zoom.us/u/abo8AwxNx2

Can we precisely rewrite the genetic code - make a single DNA spelling change - in the liver of a human being for clinical effect? YES! Scientific milestone: VERVE-101 provides first proof-of-concept for in vivo DNA base editing in humans Clinical implication: It’s early but could open the way for an entire new way to treat heart disease; instead of daily pills/intermittent injections, a one-time intravenous infusion procedure to durably (possibly lifelong) lower LDL cholesterol; "surgery without a scalpel" Takeaways: 1. 10 patients with severe HeFH and ASCVD treated so far across 4 dose levels 2. Clinical effect on LDL-C (40% - 55% reductions) at potentially therapeutic doses 3. Dose-dependent reductions in blood PCSK9 protein and blood LDL-C 4. Durability so far out to six months, consistent with the pre-clinical data in NHP where the durability is out to 2.5y after a single treatment 5. Consistent with FDA guidance on patients to enroll in a Phase 1 study of gene editing products, we enrolled the sickest of the sick coronary disease patients 6. Safety profile revealed expected LNP-infusion related events: a) transient flu-like symptoms for a few hours after infusion; b) transient, reversible rise in LFTs after infusion 7. Two patients experienced CV events consistent with their underlying severe ASCVD 8. Safety profile supports continued development (DSMB have reviewed these data and requested to continue dosing) 9. These interim heart-1 data were submitted to FDA as part of IND package and we now have clearance to start study in U.S. 10. Next steps: finish dose escalation, complete dose expansion in 2024 11. Phase 2 start in 2025 for PCSK9 program Foremost, grateful to the patients who have volunteered and their families Thankful to the amazing @VerveTx scientific and clinical team (led by @andrew Bellinger), the investigators and study staff, the independent DSMB, and our partners P.S. Deepavali celebrates new knowledge and so thrilled to add today to our knowledge on the intersection of gene editing technology and cardiovascular disease $VERV @AHAScience @AHAMeetings @American_Heart #AHA23

Exploring #ATTR in Greece. Revealing key clinical patterns & #outcomes from the National Reference Center. Impactful data for local #management! Available online: bit.ly/HJC_ATTRreg @HCSgr @hjc_ed @Georgio72461242 @Ioannis_Petrop @KimonStamatel #Cardiomyopathy #amyloidosis

3-Year Outcomes in #NSTEMI: Sex Differences Matter! Female NSTEMI patients with SBT<48h show higher #mortality. Let's reshape #prevention strategies. Available Online: bit.ly/HJC_NSTmortali… @HCSgr @hjc_ed @trv940 @DongOhKang #Cardiology #Research #RadialFirst #CardioTwitter

Can existing #risk prediction tools stratify patients with concomitant #MR & #TR undergoing TEER? Check the groundbreaking results online: bit.ly/HJCriskMR @AlonSchechter @DKaewkes @vpatelmd @dr_ofir @TarunChakrava14 @mmamas1973 @drmaisano @GreggWStone @MarcoMetra

#Cardiac metastatic #tumour  as an unusual cause of ST elevation Available online: bit.ly/HJC_tumourST @HCSgr @hjc_ed #Cancer #echofirst #Metastasis #STEMI #RadialFirst @CardioTwitter

#yesCCT for interventional cardiologists. Great piece and survey by @scottiejj12

@ekoikonomou @nih_nhlbi @cards_lab @Yale @rohan_khera Hip, hip, hooray!! Congrats!!

Thrilled to receive the #NOA for my #F32 today. Grateful to @nih_nhlbi for funding and all mentors for their support. Looking forward to applying #AI for multi-modal point-of-care screening of CV disease and working with the amazing team @cards_lab @Yale led by @rohan_khera.

Exciting to see a full moderated poster session #ESCCongress dedicated to pericoronary fat imaging by #yesCCT. Impressive progress in the field over the last 6 years. @Charis_Oxford @AlAntonopoulos

From #EHJCVI, interesting guide about the #whyCMR applications in pericardial syndromes! academic.oup.com/ehjcimaging/ar… @escardio @GeraldMaurer @denisamuraru @VDelgadoGarcia @EACVIPresident #cvimaging

Endo-Epicardial #Electrogram asynchrony features as as a tool to identify #AtrialFibrillation substrates during SR: The Asynchrony Fingerprint Score Online available: bit.ly/HJC_AFS @HCSgr @hjc_ed @mathijsvschie @nmsdegroot #Epeeps #AFib #CardioTwitter #AFprediction